A detailed history of Pdt Partners, LLC transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Pdt Partners, LLC holds 33,342 shares of ENTA stock, worth $337,754. This represents 0.03% of its overall portfolio holdings.

Number of Shares
33,342
Previous 36,243 8.0%
Holding current value
$337,754
Previous $470,000 26.6%
% of portfolio
0.03%
Previous 0.05%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.05 - $16.54 $29,155 - $47,982
-2,901 Reduced 8.0%
33,342 $345,000
Q2 2024

Aug 15, 2024

SELL
$11.43 - $17.02 $39,822 - $59,297
-3,484 Reduced 8.77%
36,243 $470,000
Q1 2024

May 15, 2024

SELL
$10.08 - $17.46 $236,859 - $410,275
-23,498 Reduced 37.17%
39,727 $693,000
Q4 2023

Feb 14, 2024

SELL
$8.18 - $10.78 $33,480 - $44,122
-4,093 Reduced 6.08%
63,225 $594,000
Q3 2023

Nov 14, 2023

BUY
$11.09 - $22.13 $440,261 - $878,538
39,699 Added 143.74%
67,318 $751,000
Q2 2023

Aug 14, 2023

BUY
$20.68 - $39.85 $571,160 - $1.1 Million
27,619 New
27,619 $591,000
Q2 2022

Aug 15, 2022

BUY
$38.13 - $76.93 $442,193 - $892,157
11,597 New
11,597 $548,000
Q4 2021

Feb 14, 2022

SELL
$60.19 - $97.37 $779,701 - $1.26 Million
-12,954 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$41.02 - $58.65 $407,984 - $583,332
-9,946 Reduced 43.43%
12,954 $736,000
Q2 2021

Aug 16, 2021

BUY
$43.76 - $53.11 $137,275 - $166,606
3,137 Added 15.87%
22,900 $1.01 Million
Q1 2021

May 17, 2021

SELL
$41.69 - $54.95 $172,471 - $227,328
-4,137 Reduced 17.31%
19,763 $975,000
Q4 2020

Feb 16, 2021

BUY
$41.16 - $47.47 $185,219 - $213,615
4,500 Added 23.2%
23,900 $1.01 Million
Q3 2020

Nov 16, 2020

SELL
$43.36 - $53.53 $413,741 - $510,783
-9,542 Reduced 32.97%
19,400 $888,000
Q2 2020

Aug 14, 2020

BUY
$46.37 - $57.58 $1.34 Million - $1.67 Million
28,942 New
28,942 $1.45 Million

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $210M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.